A detailed history of Hsbc Holdings PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 26,883 shares of DNLI stock, worth $577,715. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,883
Previous 29,642 9.31%
Holding current value
$577,715
Previous $688,000 13.81%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$20.96 - $31.05 $57,828 - $85,666
-2,759 Reduced 9.31%
26,883 $783,000
Q2 2024

Aug 12, 2024

BUY
$14.96 - $23.22 $201,271 - $312,401
13,454 Added 83.11%
29,642 $688,000
Q1 2024

May 15, 2024

SELL
$15.83 - $23.35 $11,144 - $16,438
-704 Reduced 4.17%
16,188 $332,000
Q4 2023

Feb 12, 2024

SELL
$16.2 - $23.18 $8,667 - $12,401
-535 Reduced 3.07%
16,892 $362,000
Q3 2023

Nov 13, 2023

BUY
$20.63 - $30.17 $359,519 - $525,772
17,427 New
17,427 $359,000
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $92,109 - $137,344
4,204 Added 44.97%
13,553 $312,000
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $44,019 - $56,816
1,675 Added 21.83%
9,349 $259,000
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $199,293 - $295,679
7,674 New
7,674 $239,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.